- Home
- CLFD vs PHAR Comparison
CLFD vs PHAR Comparison
Compare CLFD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLFD
- PHAR
- Stock Information
- Founded
- CLFD 1979
- PHAR 1988
- Country
- CLFD United States
- PHAR Netherlands
- Employees
- CLFD N/A
- PHAR N/A
- Industry
- CLFD Telecommunications Equipment
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CLFD Utilities
- PHAR Health Care
- Exchange
- CLFD Nasdaq
- PHAR Nasdaq
- Market Cap
- CLFD 608.6M
- PHAR 707.9M
- IPO Year
- CLFD N/A
- PHAR N/A
- Fundamental
- Price
- CLFD $40.81
- PHAR $10.96
- Analyst Decision
- CLFD Strong Buy
- PHAR Strong Buy
- Analyst Count
- CLFD 3
- PHAR 3
- Target Price
- CLFD $46.67
- PHAR $30.00
- AVG Volume (30 Days)
- CLFD 131.7K
- PHAR 5.3K
- Earning Date
- CLFD 08-06-2025
- PHAR 07-31-2025
- Dividend Yield
- CLFD N/A
- PHAR N/A
- EPS Growth
- CLFD N/A
- PHAR N/A
- EPS
- CLFD N/A
- PHAR N/A
- Revenue
- CLFD $178,209,000.00
- PHAR $339,836,000.00
- Revenue This Year
- CLFD $10.77
- PHAR $12.88
- Revenue Next Year
- CLFD $14.46
- PHAR $8.54
- P/E Ratio
- CLFD N/A
- PHAR N/A
- Revenue Growth
- CLFD N/A
- PHAR 22.44
- 52 Week Low
- CLFD $23.78
- PHAR $6.73
- 52 Week High
- CLFD $46.76
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- CLFD 41.48
- PHAR 58.06
- Support Level
- CLFD $43.00
- PHAR $9.54
- Resistance Level
- CLFD $45.90
- PHAR $10.46
- Average True Range (ATR)
- CLFD 1.60
- PHAR 0.37
- MACD
- CLFD -0.34
- PHAR 0.10
- Stochastic Oscillator
- CLFD 0.34
- PHAR 81.20
About CLFD Clearfield Inc.
Clearfield Inc mainly designs, manufactures, and distributes fiber protection, fiber management and fiber delivery solutions for communications networks. It provides a various products including copper assemblies, cassettes, box enclosures, fiber connectors, frames, microduct, terminals, vaults, pedestal inserts, FieldSmart, WaveSmart, and CraftSmart. The company has international presence with the majority of the revenue derived from the United States. The company has two reportable segments namely Clearfield segment and Nestor cables segment. The majority of revenue is derived from Clearfield segment.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.